144 related articles for article (PubMed ID: 23902722)
21. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
22. miR-99a promotes proliferation targeting FGFR3 in human epithelial ovarian cancer cells.
Jiang H; Qu L; Wang Y; Cong J; Wang W; Yang X
Biomed Pharmacother; 2014 Mar; 68(2):163-9. PubMed ID: 24456664
[TBL] [Abstract][Full Text] [Related]
23. The Crosstalk between Nrf2 and TGF-β1 in the Epithelial-Mesenchymal Transition of Pancreatic Duct Epithelial Cells.
Arfmann-Knübel S; Struck B; Genrich G; Helm O; Sipos B; Sebens S; Schäfer H
PLoS One; 2015; 10(7):e0132978. PubMed ID: 26226105
[TBL] [Abstract][Full Text] [Related]
24. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
[TBL] [Abstract][Full Text] [Related]
25. FGFR3 signaling and function in triple negative breast cancer.
Chew NJ; Nguyen EV; Su SP; Novy K; Chan HC; Nguyen LK; Luu J; Simpson KJ; Lee RS; Daly RJ
Cell Commun Signal; 2020 Jan; 18(1):13. PubMed ID: 31987043
[TBL] [Abstract][Full Text] [Related]
26. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.
Mahe M; Dufour F; Neyret-Kahn H; Moreno-Vega A; Beraud C; Shi M; Hamaidi I; Sanchez-Quiles V; Krucker C; Dorland-Galliot M; Chapeaublanc E; Nicolle R; Lang H; Pouponnot C; Massfelder T; Radvanyi F; Bernard-Pierrot I
EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29463565
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.
Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Satoh Y; Ishii N; Aoki M
Mol Cancer Ther; 2015 Mar; 14(3):704-12. PubMed ID: 25589496
[TBL] [Abstract][Full Text] [Related]
28. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
[TBL] [Abstract][Full Text] [Related]
29. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
[TBL] [Abstract][Full Text] [Related]
30. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
31. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
[TBL] [Abstract][Full Text] [Related]
32. Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma.
Paur J; Valler M; Sienel R; Taxauer K; Holzmann K; Marian B; Unterberger A; Mohr T; Berger W; Gvozdenovich A; Schimming J; Grusch M; Grasl-Kraupp B
Liver Int; 2020 Sep; 40(9):2279-2290. PubMed ID: 32378800
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic FGFR3 gene fusions in bladder cancer.
Williams SV; Hurst CD; Knowles MA
Hum Mol Genet; 2013 Feb; 22(4):795-803. PubMed ID: 23175443
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.
Cheng T; Roth B; Choi W; Black PC; Dinney C; McConkey DJ
PLoS One; 2013; 8(2):e57284. PubMed ID: 23468956
[TBL] [Abstract][Full Text] [Related]
35. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
Li C; Chen L; Iwata T; Kitagawa M; Fu XY; Deng CX
Hum Mol Genet; 1999 Jan; 8(1):35-44. PubMed ID: 9887329
[TBL] [Abstract][Full Text] [Related]
36. Measurement of FGFR3 signaling at the cell membrane via total internal reflection fluorescence microscopy to compare the activation of FGFR3 mutants.
Hartl I; Brumovska V; Striedner Y; Yasari A; Schütz GJ; Sevcsik E; Tiemann-Boege I
J Biol Chem; 2023 Feb; 299(2):102832. PubMed ID: 36581204
[TBL] [Abstract][Full Text] [Related]
37. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
[TBL] [Abstract][Full Text] [Related]
38. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.
Jin M; Yu Y; Qi H; Xie Y; Su N; Wang X; Tan Q; Luo F; Zhu Y; Wang Q; Du X; Xian CJ; Liu P; Huang H; Shen Y; Deng CX; Chen D; Chen L
Hum Mol Genet; 2012 Dec; 21(26):5443-55. PubMed ID: 23014564
[TBL] [Abstract][Full Text] [Related]
39. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
40. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma.
Hanlon L; Avila JL; Demarest RM; Troutman S; Allen M; Ratti F; Rustgi AK; Stanger BZ; Radtke F; Adsay V; Long F; Capobianco AJ; Kissil JL
Cancer Res; 2010 Jun; 70(11):4280-6. PubMed ID: 20484026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
